Fig. 1From: Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studiesThe COMPARZ study design. AE, adverse event; FU, follow-up; PD, progressive diseaseBack to article page